NX Development Corp. News & Updates

Catch our latest press releases, scientific updates, and company milestones.

April 6, 2026

NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study

 

Press Release

April 24, 2025

Sales and Marketing Rights of Gleolan® (aminolevulinic acid HCl) Return to NX Development Corp.

Press Release

June 21, 2024

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan®

Press Release

March 5, 2024

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers

Press Release

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers